DE69903992D1 - Heterocyclische Carboxamide - Google Patents

Heterocyclische Carboxamide

Info

Publication number
DE69903992D1
DE69903992D1 DE69903992T DE69903992T DE69903992D1 DE 69903992 D1 DE69903992 D1 DE 69903992D1 DE 69903992 T DE69903992 T DE 69903992T DE 69903992 T DE69903992 T DE 69903992T DE 69903992 D1 DE69903992 D1 DE 69903992D1
Authority
DE
Germany
Prior art keywords
heterocyclic carboxamides
carboxamides
heterocyclic
agonist
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69903992T
Other languages
English (en)
Other versions
DE69903992T2 (de
Inventor
Harry Ralph Howard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of DE69903992D1 publication Critical patent/DE69903992D1/de
Application granted granted Critical
Publication of DE69903992T2 publication Critical patent/DE69903992T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
DE69903992T 1998-04-15 1999-03-25 Heterocyclische Carboxamide Expired - Fee Related DE69903992T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8179098P 1998-04-15 1998-04-15

Publications (2)

Publication Number Publication Date
DE69903992D1 true DE69903992D1 (de) 2003-01-02
DE69903992T2 DE69903992T2 (de) 2003-08-21

Family

ID=22166430

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69903992T Expired - Fee Related DE69903992T2 (de) 1998-04-15 1999-03-25 Heterocyclische Carboxamide

Country Status (10)

Country Link
US (4) US6277852B1 (de)
EP (1) EP0957099B1 (de)
JP (1) JP3224372B2 (de)
AT (1) ATE228119T1 (de)
BR (1) BR9901052A (de)
CA (1) CA2268870C (de)
DE (1) DE69903992T2 (de)
DK (1) DK0957099T3 (de)
ES (1) ES2188095T3 (de)
PT (1) PT957099E (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2188095T3 (es) * 1998-04-15 2003-06-16 Pfizer Prod Inc Carboxamidas heterociclicas.
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
ATE409475T1 (de) * 2001-02-20 2008-10-15 Dinan Timothy Gerard Behandlung von fibromyalgie mit pindolol
CA2443050A1 (en) * 2001-03-30 2002-10-10 Philadelphia Health And Education Corporation Immunomodulation and effect on cell processes relating to serotonin family receptors
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
AU2002344854B2 (en) * 2001-06-11 2008-11-06 Vertex Pharmaceuticals (Canada) Incorporated Thiophene derivatives as antiviral agents for flavivirus infection
AU2002343545A1 (en) * 2001-10-19 2003-06-10 Auburn University Estimating reliability of components for testing and quality optimization
ES2345438T3 (es) 2002-12-10 2010-09-23 Virochem Pharma Inc. Compuestos y metodos para el tratamiento o prevencion de infecciones por flavivirus.
EP1809104A4 (de) * 2004-09-23 2009-04-29 Alexander Michalow Verfahren zum regeln von neurotransmittersystemen durch gegenadaptationen
SG161315A1 (en) * 2005-05-13 2010-05-27 Virochem Pharma Inc Compounds and methods for the treatment or prevention of flavivirus infections
JP5498703B2 (ja) 2006-01-23 2014-05-21 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチオフェン−カルボキサミド
CN101466708A (zh) 2006-04-13 2009-06-24 弗特克斯药品有限公司 可用作蛋白激酶抑制剂的噻吩甲酰胺
EP2027116A2 (de) * 2006-05-23 2009-02-25 Vertex Pharmaceuticals Incorporated Als protein-kinase-inhibitoren nutzbare thiophen-carboxamide
CN101495474A (zh) 2006-05-23 2009-07-29 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的噻吩-甲酰胺类
DE102006027229A1 (de) 2006-06-09 2007-12-20 Grünenthal GmbH 1,3-Disubstituierte 4-Methyl-1H-pyrrol-2-carbonsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
PL2104674T3 (pl) 2006-11-15 2013-12-31 Vertex Pharmaceuticals Canada Incorporated Analogi tiofenu do leczenia lub zapobiegania zakażeniom flawiwirusowym
GB0701970D0 (en) * 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
JP5645663B2 (ja) 2007-08-15 2014-12-24 プレジデント アンド フェローズ オブ ハーバード カレッジ ネクロトーシスのヘテロ環式抑制剤
EP2576532B1 (de) 2010-06-07 2018-07-18 Novomedix, LLC Furanylverbindungen und ihre verwendung
WO2013161871A1 (ja) * 2012-04-25 2013-10-31 興和株式会社 Ｔｌｒ阻害作用を有するチオフェン誘導体
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP2968276A4 (de) 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybride nekroptoseinhibitoren
EP3116501A1 (de) 2014-03-13 2017-01-18 Proteostasis Therapeutics, Inc. Verbindungen, zusammensetzungen und verfahren zur steigerung der cftr-aktivität
CA2942387A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr actvity
US9926286B2 (en) * 2014-05-09 2018-03-27 Shanghai Syncores Technologies Inc. Ltd. Vortioxetine intermediate and synthesis process thereof
EP3157917B1 (de) 2014-06-19 2020-03-18 Proteostasis Therapeutics, Inc. Verbindungen, zusammensetzungen und verfahren zur steigerung der cftr-aktivität
WO2016105468A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10392378B2 (en) 2014-12-23 2019-08-27 Proteostasis Therapeutics, Inc. Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MA41253A (fr) * 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
WO2016105484A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MA42488A (fr) 2015-07-24 2018-05-30 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
NZ741093A (en) 2015-10-06 2022-12-23 Proteostasis Therapeutics Inc Compounds, compositions, and methods for modulating cftr
SG11201808682XA (en) 2016-04-07 2018-11-29 Proteostasis Therapeutics Inc Silicone atoms containing ivacaftor analogues
AU2017280206A1 (en) 2016-06-21 2019-01-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
EP3366683A1 (de) 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Zyklische amide, acetamide und harnstoffe als kalium kanal öffner
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
FR2631625B1 (fr) * 1988-05-17 1992-10-16 Synthelabo Derives de phenyl-6 piperazinylalkyl-3 1h,3h-pyrimidinedione-2,4, leur preparation et leur application en therapeutique
US5130338A (en) * 1989-08-30 1992-07-14 Pfizer Inc. Method of treating chemical dependencies using sertraline
FR2655988B1 (fr) * 1989-12-20 1994-05-20 Adir Cie Nouveaux derives de la napht-1-yl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DK0689536T3 (da) * 1993-03-16 2001-07-30 Pfizer Naphthalenderivater
JPH09504004A (ja) * 1993-08-20 1997-04-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ１ｄレセプター拮抗薬用アミドおよび尿素誘導体
GB9410512D0 (en) * 1994-05-25 1994-07-13 Smithkline Beecham Plc Novel treatment
ES2188095T3 (es) * 1998-04-15 2003-06-16 Pfizer Prod Inc Carboxamidas heterociclicas.
US6492385B2 (en) * 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease

Also Published As

Publication number Publication date
US6602874B2 (en) 2003-08-05
ES2188095T3 (es) 2003-06-16
US20020002168A1 (en) 2002-01-03
US20030232841A1 (en) 2003-12-18
US20010041705A1 (en) 2001-11-15
JPH11322711A (ja) 1999-11-24
CA2268870A1 (en) 1999-10-15
US6537995B2 (en) 2003-03-25
BR9901052A (pt) 2000-04-25
US6277852B1 (en) 2001-08-21
EP0957099A2 (de) 1999-11-17
JP3224372B2 (ja) 2001-10-29
PT957099E (pt) 2003-02-28
DE69903992T2 (de) 2003-08-21
ATE228119T1 (de) 2002-12-15
EP0957099A3 (de) 1999-11-24
CA2268870C (en) 2005-03-29
EP0957099B1 (de) 2002-11-20
DK0957099T3 (da) 2003-03-17

Similar Documents

Publication Publication Date Title
ATE228119T1 (de) Heterocyclische carboxamide
DK0952154T3 (da) N-acyl- og N-aroylaralkylamider
GB9801690D0 (en) Therapeutic agents
ATE218859T1 (de) Liganden des neuropeptids y
DE59914814D1 (de) Heterozyklische substituierte amide, deren herstellung und anwendung
ES2194960T3 (es) N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f.
DK1109817T3 (da) Phosphohalogenhydriner, deres fremstilling og anvendelse
ATE177096T1 (de) 4-substituierte 1,2,4-triazolderivate
DE69708968D1 (de) Arylacrylamidderivate als 5HT1 Agoniste oder Antagoniste
ID23053A (id) Karboksamida yang digunakan sebagai agonis 5-ht <if>
BG105710A (en) 5ht1 antagonists for antidepressant therapy
BR0201569A (pt) 4-(2-piridil) piperizinas possuindo uma atividade agonista do receptor 5ht7
MA25653A1 (fr) Derives d'amides heterocycliques.
DK1049672T3 (da) Azetidincarboxamid-derivater til behandling af CNS-lidelser
DE69922918D1 (de) Neuropeptid Y Antagonisten
EA200001104A1 (ru) Аскорбат пароксетина
SE9901237D0 (sv) Novel use

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee